All In MedTech

Device Trial Radar · NCT07122518

Post-Approval Study of PALMAZ MULLINS XD™ in Treating Pulmonary Artery Stenosis

A Post-Approval Evaluation of the PALMAZ MULLINS XD™ Pulmonary Stent in the Treatment of Pulmonary Artery Stenosis (REALPASS)

Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

35

Planned (sponsor's estimate)

Start

Jun 23, 2026

Primary completion

Jun 2028

Study completion Jun 2028

Sponsor

Lead sponsor
Cordis US Corp.Not on our public-company list
Sponsor type
Industry
Collaborators
Congenital Cardiovascular Interventional Study Consortium (CCISC)
First posted
Aug 14, 2025

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the clinical investigation is to characterize clinical outcomes and to assess the real-world use of the commercial PALMAZ MULLINS XD™ Pulmonary Stent.

Conditions

  • Pulmonary Artery Stenosis

Interventions

  • PALMAZ MULLINS XD™ Pulmonary StentDevice

    The PALMAZ MULLINS XD™ Pulmonary Stent is indicated for the non-emergency treatment of pulmonary artery stenosis in pediatric patients who are at least 10kg in weight with two ventricle anatomy. The PALMAZ MULLINS XD™ Pulmonary Stent is a balloon-expandable, laser cut stent made from 316L stainless steel tubing. The stent is supplied unmounted and in five (5) nominal unexpanded lengths: 19 mm, 25 mm, 29 mm, 39 mm, and 59 mm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Technical Success (Successful use of the study device without additional, unplanned device or procedure-related surgery/re-intervention)Time frame: Start time of index procedure through time of discharge/study completion, usually within ~48 hours from end time of index procedure
  2. Patency (Angiographically-determined increase in stented vessel minimum pulmonary artery diameter by ≥ 50% of the pre-stent diameter)Time frame: Index procedure (start time to end time)
  3. Safety Outcome (Incidence of Treatment-Emergent Serious Adverse Events)Time frame: Time of enrollment (device implant during index procedure) through time of discharge/study completion, usually within ~48 hours from end time of index procedure

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • UC Davis Children's Hospital

    Sacramento, California · Not yet recruiting

  • Children's Healthcare of Atlanta

    Atlanta, Georgia · Not yet recruiting

  • Children's Hospital of Michigan

    Detroit, Michigan · Recruiting

5 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.